drugset / Trial / NCT05919537
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
Timeline
- Start
- 2023-09-06
- Primary completion
- 2031-03-01
- Completion
- 2031-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | NEZUTATUG | Monoclonal antibody | — | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |